ECC 2013 Immuno-Oncology Satellite Symposium supported by Bristol-Myers Squibb. Immuno-Oncology: the next new paradigm in cancer treatment?

Current data with immuno-oncology therapies are encouraging and show activity across multiple tumour types. Prof. Johnson discusses how we can now begin to realise their true potential and ensure optimal integration with current standards of care including when to use, how to use with other therapies and how to select patients who may benefit from these therapies.

To view the slides fullscreen click the square and arrows button at the bottom right of the player.